This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): zafirlukast
Description: Accolate is an oral, selective, andcompetitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). In the lung, leukotrienes are thought to be involved with increasing mucus production, airway irritability and swelling, and smooth muscle constriction. Leukotrienes are also involved in the inflammatory process.
Pink Sheet In Brief: Zeneca's Accolate
Pink Sheet AstraZeneca Accolate
Additional information available to subscribers only: